nach oben

Current Diabetes Reports

Erschienen in:

01.12.2019 | Hospital Management of Diabetes (A Wallia and JJ Seley, Section Editors)

Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients

verfasst von: Amy Hiestand, James Flory, Ritika Chitkara

Erschienen in: Current Diabetes Reports | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Many patients experience hyperglycemia during cancer treatment, either as a new-onset condition or as an exacerbation of existing diabetes. This can impact treatment and outcomes, increasing the risk of complications and worsening health-related quality of life (HRQoL). These issues may be particularly significant when patients are hospitalized and/or acutely ill. The purpose of this review is to identify common barriers and strategies specific to the inpatient setting to improve glycemic control and minimize complications both while patients are hospitalized and after discharge.

Recent Findings

Hyperglycemia in patients who are hospitalized during cancer treatment is common, but there is a lack of consensus on goals and approaches to glycemic management in this setting. Hyperglycemia related to oncology treatment can have unusual causes and challenges in management. Organizational guidelines can help standardize treatment and guide providers in managing hyperglycemia in oncology patients during hospitalization and upon discharge. Hospitalization is a critical period that provides an opportunity to reassess and modify management plans, coordinate follow-up care, and, crucially, educate and empower patients to successfully manage their blood glucose levels once they are discharged. Emerging technology such as patient portals can facilitate hyperglycemia management after discharge.

Summary

This review discusses evidences and strategies to utilize the period of hospitalization to develop and implement an individualized plan of care for patients with concurrent hyperglycemia and cancer.

•• Hershey DS. Importance of glycemic control in cancer patients with diabetes: treatment through end of life. Asia Pac J Oncol Nurs. 2017;4(4):313–8. This article highlights not only the important role of but also some of the challenges to glycemic management throughout the cancer treatment continuum. Emphasizing the need for consensus regarding goals of treatment and the individualized needs of this special subset of the diabetes population.PubMedPubMedCentral

Psarakis HM. Clinical challenges in caring for patients with diabetes and cancer. Diabetes Spectr. 2006;19(3):157–62.

Barone BB, Yeh HC, Snyder CF, Peairs KS, Stein KB, Derr RL, et al. Postoperative mortality in cancer patients with preexisting diabetes: systematic review and meta-analysis. Diabetes Care. 2010;33(4):931–9.PubMedPubMedCentral

Duan W, Shen X, Lei J, Xu Q, Yu Y, Li R, et al. Hyperglycemia, a neglected factor during cancer progression. Biomed Res Int. 2014.

Overbeek JA, van Herk-Sukel MP, Vissers PA, van der Heijden AA, Bronsveld HK, Herings RM, et al. Type 2 diabetes, but not insulin (analog) treatment, is associated with more advanced stages of breast cancer: a national linkage of cancer and pharmacy registries. Diabetes Care. 2019;42(3):434–42.PubMed

Zhu B, Wu X, Wu B, Pei D, Zhang L, Wei L. The relationship between diabetes and colorectal cancer prognosis: a meta-analysis based on the cohort studies. PLoS One. 2017;12(4):e0176068.PubMedPubMedCentral

Karlin NJ, Cheng MR, Castro JC, Cook CB. Hyperglycemia among hospitalized cancer patients with coexisting diabetes mellitus. Diabetes Manag. 2015;5(6):441–8.

Goebel J, Valinski S, Hershey DS. Improving coordination of care among healthcare professionals and patients with diabetes and cancer. Clin J Oncol Nurs. 2016:20(6).PubMed

American Diabetes Association. 12. Older adults: standards of medical care in diabetes-2019. Diabetes Care 42(Suppl 1):S139-S47.

10.

LeRoith D, Biessels GJ, Braithwaite SS, Casanueva FF, Draznin B, Halter JB, et al. Treatment of diabetes in older adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520–74.PubMedPubMedCentral

11.

Dunning T, Savage S, Duggan N, Martin P. Palliative and end of life care for people with diabetes: a topical issue. Diabetes Manag. 2014;4(5):449.

12.

Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary. J Oncol Pract. 2017;13(2):119–21.PubMed

13.

National Cancer Institute. April 27, Cancer statistics. 2018 Available from https://www.cancer.gov/about-cancer/understanding/statistics. Accessed 16 May 2019.

14.

Royal Australian College of General Practitioners (RACGP). General practice management of type 2 diabetes: 2016–18. 2016. Available from https://static.diabetesaustralia.com.au/s/fileassets/diabetes-australia/5d3298b2-abf3-487e-9d5e-0558566fc242.pdf. Accessed May 1 2019.

15.

Ferrari P, Giardini A, Negri EM, Villani G, Preti P. Managing people with diabetes during the cancer palliation in the era of simultaneous care. Diabetes Res Clin Pract. 2018;143:443–53.PubMed

16.

King EJ, Haboubi H, Evans D, Baker I, Bain SC, Stephens JW. The management of diabetes in terminal illness related to cancer. QJM: International J Med. 2011;105(1):3–9.

17.

McCoubrie R, Jeffrey D, Paton C, Dawes L. Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care. 2005;14(3):244–8.

18.

•• Gallo M, Muscogiuri G, Felicetti F, Faggiano A, Trimarchi F, Arvat E, et al. Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. Metabolism. 2018;78:141–54. Reviews the coexistence of diabetes and cancer and the complications that often arise as a consequence of the comorbidity. Addresses some of the challenges of oncologic management and end-of-life care in patients with diabetes.PubMed

19.

Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096–106.PubMedPubMedCentral

20.

Lossignol D. A little help from steroids in oncology. J Transl Int Med. 2016;4(1):52–4.PubMedPubMedCentral

21.

•• Suh S, Park MK. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab. 2017;32(2):180–9. This article addresses the problem of hyperglycemia while receiving glucocorticoids. Treatment of steroid-induced hyperglycemia tends be overlooked but can cause complications and poorer outcomes for patients with diabetes, as well as those without diabetes. They identify some common challenges in addition to treatment strategies and screening guidelines.

22.

Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6(8):1073–81.PubMedPubMedCentral

23.

Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2006;18(2):233–40.PubMed

24.

Moreno A, Colon-Otero G, Solberg LA. The prednisone dosage in the CHOP chemotherapy regimen for non-Hodgkin’s lymphomas (NHL): is there a standard? Oncologist. 2000;5(3):238–49.PubMed

25.

Korytkowski MT. In-patient management of diabetes: controversies and guidelines. Indian J Endocrinol Metab. 2013;17(Suppl 3):S630–5.PubMedPubMedCentral

26.

Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125(4):606–15.PubMedPubMedCentral

27.

Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98.PubMed

28.

Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.PubMedPubMedCentral

29.

Wang YY, Hu SF, Ying HM, Chen L, Li HL, Tian F, et al. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis. BMC Endocr Disord. 2018;18(1):42.PubMedPubMedCentral

30.

Kang Z, Huo JL, Zhai XJ. Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis. Endocr Connect 2018;1(aop).

31.

De Bruijn KM, van Eijck CH. New-onset diabetes after distal pancreatectomy: a systematic review. Ann Surg. 2015;261(5):854–61.PubMed

32.

Henry RR, Ciaraldi TP, Armstrong D, Burke P, Ligueros-Saylan M, Mudaliar S. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013;98(8):3446–53.PubMed

33.

Zakaria HM, Stauffer JA, Raimondo M, Woodward TA, Wallace MB, Asbun HJ. Total pancreatectomy: short- and long-term outcomes at a high-volume pancreas center. World J Gastrointest Surg. 2016;8(9):634–42.PubMedPubMedCentral

34.

Cappelli LC, Shah AA, Bingham CO. Immune-related adverse effects of cancer immunotherapy—implications for rheumatology. Rheum Dis Clin N Am. 2017;43(1):65–78.

35.

Girotra M, Hansen A, Farooki A, Byun DJ, Min L, Creelan BC, et al. The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2018;2(3):pky021.PubMedPubMedCentral

36.

Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.PubMed

37.

Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, et al. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. J Immunother Cancer. 2017;5(1):40.PubMedPubMedCentral

38.

Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471–80.PubMedPubMedCentral

39.

Kotwal A, Haddox C, Block M, Kudva YC. Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care. 2019;7(1):e000591.PubMedPubMedCentral

40.

Sauer AC. Malnutrition in patients with cancer: an often overlooked and undertreated problem. Oncology Nurse 2013. Available www.theoncologynurse.com/ton-issue-archive/2013-issues/october-vol-6-no-9/16012-malnutrition-in-patients-with-cancer-an-often-overlooked-and-undertreated-problem. Accessed 15 June 2019.

41.

Planas M, Álvarez-Hernández J, León-Sanz M, Celaya-Pérez S, Araujo K, De Lorenzo AG. Prevalence of hospital malnutrition in cancer patients: a sub-analysis of the PREDyCES® study. Support Care Cancer. 2016;24(1):429–35.PubMed

42.

Corbett T, Bridges J. Multimorbidity in older adults living with and beyond cancer. Curr Opin Support Palliat Care. 2019;13(3):220–4.PubMed

43.

Mabrey ME, Barton AB, Corsino L, Freeman SB, Davis ED, Bell EL, et al. Managing hyperglycemia and diabetes in patients receiving enteral feedings: a health system approach. Hosp Pract. 2015;43(2):74–8.

44.

Gosmanov AR, Umpierrez GE. Management of hyperglycemia during enteral and parenteral nutrition therapy. Curr Diab Rep. 2013;13(1):155–62.PubMedPubMedCentral

45.

Umpierrez GE. Basal versus sliding-scale regular insulin in hospitalized patients with hyperglycemia during enteral nutrition therapy. Diabetes Care. 2009;32(4):751–3.PubMedPubMedCentral

46.

Korytkowski MT, Salata RJ, Koerbel GL, Selzer F, Karslioglu E, Idriss AM, et al. Insulin therapy and glycemic control in hospitalized patients with diabetes during enteral nutrition therapy: a randomized controlled clinical trial. Diabetes Care. 2009;32(4):594–6.PubMedPubMedCentral

47.

Viana MV, Viana LV, Tavares AL, de Azevedo MJ. Insulin regimens to treat hyperglycemia in hospitalized patients on nutritional support: systematic review and meta-analyses. Ann Nutr Metab. 2017;71(3–4):183–94.

48.

Vennard KC, Selen DJ, Gilbert MP. The management of hyperglycemia in noncritically ill hospitalized patients treated with continuous enteral or parenteral nutrition. Endocr Pract. 2018;24(10):900–6.PubMed

49.

Miaskowski C, Dodd M, West C, Schumacher K, Paul SM, Tripathy D, et al. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. J Clin Oncol. 2004;22(9):1713–20.PubMed

50.

Hartigan K. Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs. 2003;7(6 Suppl):21–4.PubMed

51.

Jivraj N, Gallagher LO, Papadakos J, Abdelmutti N, Trang A, Ferguson SE. Empowering patients and caregivers with knowledge: the development of a nurse-led gynecologic oncology chemotherapy education class. Can Oncol Nurs J. 2018;28(1):4–7.PubMedPubMedCentral

52.

Poland F, Spalding N, Gregory S, McCulloch J, Sargen K, Vicary P. Developing patient education to enhance recovery after colorectal surgery through action research: a qualitative study. BMJ Open. 2017;7(6):e013498.PubMedPubMedCentral

53.

Ryan-Madonna M, Levin RF, Lauder B. Effectiveness of the teach-back method for improving caregivers’ confidence in caring for hospice patients and decreasing hospitalizations. J Hosp Palliat Nurs. 2019;21(1):61–70.PubMed

54.

Yen PH, Leasure AR. Use and effectiveness of the teach-back method in patient education and health outcomes. Fed Pract. 2019;36(6):284–9.PubMedPubMedCentral

55.

Mohebi S, Azadbakht L, Feizi A, Sharifirad G, Kargar M. Review the key role of self-efficacy in diabetes care. J Educ Health Promot. 2013;2:36.PubMedPubMedCentral

56.

Modic MB, Vanderbilt A, Siedlecki SL, Sauvey R, Kaser N, Yager C. Diabetes management unawareness: what do bedside nurses know? Appl Nurs Res. 2014;27(3):157–61.PubMed

57.

Krall JS, Donihi AC, Hatam M, Koshinsky J, Siminerio L. The nurse education and transition (NEAT) model: educating the hospitalized patient with diabetes. Clin Diabetes Endocrinol. 2016;2(1):1.PubMedPubMedCentral

58.

Nettles AT. Patient education in the hospital. Diabetes Spectr. 2005;18(1):44–8.

59.

Amuta-Jimenez AO, Lo C, Talwar D, Khan N, Barry AE. Food label literacy and use among US adults diagnosed with cancer: results from a national representative study. J Cancer Educ. 2018:1–0.

60.

Sonbol MB, Jain T, Firwana B, Hilal T, Deleon T, Murad A, et al. Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis. BMJ Support Palliat Care 2019: bmjspcare-2018.

61.

Coa KI, Epstein JB, Ettinger D, Jatoi A, McManus K, Platek ME, et al. The impact of cancer treatment on the diets and food preferences of patients receiving outpatient treatment. Nutr Cancer. 2015;67(2):339–53.PubMedPubMedCentral

62.

Mayr P, Kuhn KS, Klein P, Stover JF, Pestana EA. A diabetes-specific oral nutritional supplement improves glycaemic control in type 2 diabetes patients. Exp Clin Endocrinol Diabetes. 2016;124(7):401–9.PubMed

63.

Giannoccaro MP, Cossins J, Sørland K, Fluge Ø, Vincent A. Searching for serum antibodies to neuronal proteins in patients with myalgic encephalopathy/chronic fatigue syndrome. Clin Ther. 2019;41(5):836–47.PubMed

64.

Bower JE. The role of neuro-immune interactions in cancer-related fatigue: biobehavioral risk factors and mechanisms. Cancer. 2019;125(3):353–64.PubMed

65.

Kessels E, Husson O, Van der Feltz-Cornelis CM. The effect of exercise on cancer-related fatigue in cancer survivors: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2018;14:479–94.PubMedPubMedCentral

66.

Patel JG, Bhise AR. Effect of aerobic exercise on cancer-related fatigue. Indian J Palliat Care. 2017;23(4):355–61.PubMedPubMedCentral

67.

Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer Treat Rev. 2017;52:91–104.PubMed

68.

Larsen JJ, Dela F, Kjaer M, Galbo H. The effect of moderate exercise on postprandial glucose homeostasis in NIDDM patients. Diabetologia. 1997;40(4):447–53.PubMed

69.

Adams OP. The impact of brief high-intensity exercise on blood glucose levels. Diabetes Metab Syndr Obes. 2013;6:113–22.PubMedPubMedCentral

70.

Coughlin SS, Caplan L, Young L. A review of web portal use by oncology patients. J Cancer Treatment Diagn. 2018:2(6).

71.

Grossman LV, Masterson Creber RM, Benda NC, Wright D, Vawdrey DK, Ancker JS. Interventions to increase patient portal use in vulnerable populations: a systematic review. J Am Med Inform Assoc. 2019;26(8–9):855–70.PubMedPubMedCentral

72.

Wolff JL, Berger A, Clarke D, Green JA, Stametz R, Yule C, et al. Patients, care partners, and shared access to the patient portal: online practices at an integrated health system. J Am Med Inform Assoc. 2016;23(6):1150–8.PubMed

Titel: Hospitalization as an Opportunity to Optimize Glycemic Control in Oncology Patients
verfasst von: Amy Hiestand
James Flory
Ritika Chitkara
Publikationsdatum: 01.12.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 12/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1283-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Diabetes and Cardiovascular Disease: an Update

Pancreatic Islet Transcriptional Enhancers and Diabetes

Academic Detailing in the New Era of Diabetes Medication Management

Diagnostic Strategies for Gestational Diabetes Mellitus: Review of Current Evidence

Technological Advancements in the Management of Type 2 Diabetes

Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration